Less Invasive Solutions
The Convenience and Effectiveness of Bioventus Active Healing Therapies
At Bioventus, the Active Healing Therapies portfolio of products provide more treatment alternatives to patients – safe, effective solutions that help patients return to their active lifestyles. By speeding recovery time while avoiding invasive procedures, patients will be able to get back on their feet in ways that are more in tune with their daily lifestyles.
Ultrasound Therapy to Heal Non-union* Fractures
When it comes to non-union fractures, it can seem that surgery is the only option. EXOGEN is a great treatment alternative to surgery with a very high success rate, and is the only technology approved by the FDA to accelerate the healing of indicated* fresh fractures and bones that won’t heal on their own. As the ultrasound device can be used right in the patient’s home, EXOGEN is not only less invasive, but also much less disruptive treatment alternative to surgical options.
Only EXOGEN uses low intensity, pulsed ultrasound (LIPUS) technology to stimulate a clear biological response at a cellular level. The EXOGEN ultrasound penetrates down to the fracture, activating cell surface mechareceptors called integrins, initiating an intracellular cascade leading to upregulation. The increasing of the upregulation of genes and expression of proteins and growth factors are critical to bone healing.
In short, EXOGEN has been shown to:
- Speed bone healing of indicated fresh fractures by 38%1, 2
- Heal 86% of non-union† fractures3
- Reduce fracture treatments costs by as much as $15,0004
Learn more about how EXOGEN® can be the perfect alternative to surgery.
BONES Studies Information
Announced in March of 2017, Bioventus has commissioned an innovative series of clinical studies to further validate the ability of the EXOGEN® Ultrasound Bone Healing System to mitigate the risk of a fracture progressing to nonunion in the presence of known risk factors. Learn more at https://www.bioventusglobal.com/news/bones-overview/
Long-lasting Pain Relief and Increased Mobility with Our Joint Therapies
When osteoarthritis strikes at joints like the knee, the synovial fluid that keeps the joint lubricated is depleted. Not only can this cause significant pain in the patient, but the lack of lubrication can also cause so much wear and tear of the joint that a total joint replacement can become necessary.
Our therapies replace the lubricating and shock-absorbing properties of the synovial fluid. Our treatments, delivered as injections, inserts HA directly into the joint, restoring the synovial fluid to its former strength. Not only does this provide long-term pain relief that can lasts for months, but the new lubrication also helps to further reduce joint pain.
Discover how our joint injection therapies are the solution osteoarthritis patients need. Our treatments can be administered right in the physician’s office, taking only 10-15 minutes to administer.
Learn more about our joint injection therapies here:
Health care providers inside the U.S. can learn about SUPARTZ FX® by visiting www.SUPARTZFX.com. Health care providers outside the U.S. can learn about DUROLANE® by visiting www.durolane.com.
1. Heckman JD, Ryaby JP, McCabe J, Frey JJ, Kilcoyne RF. Acceleration of tibial fracture-healing by non-invasive, low-intensity pulsed ultrasound. J Bone Joint Surg Am. 1994;76(1):26-34.
2. Kristiansen TK, Ryaby JP, McCabe J, Frey JJ, Roe LR. Accelerated healing of distal radial fractures with the use of specific, low-intensity ultrasound. A multicenter, prospective, randomized, double-blind, placebo-controlled study. J Bone Joint Surg Am. 1997;79(7):961-73.
3. Nolte PA, van der Krans A, Patka P, Janssen IM, Ryaby JP, Albers GH. Low-intensity pulsed ultrasound in the treatment of nonunions. J Trauma. 2001;51(4):693-703.
4. Heckman JD, Sarasohn-Kahn J. The economics of treating tibia fractures. The cost of delayed unions. Bull Hosp Jt Dis. 1997;56(1):63-72.
*EXOGEN Summary of Indications for Use: The EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established non-unions† excluding skull and vertebra. In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization.
There are no known contraindications for the EXOGEN device. Safety and effectiveness has not been established for individuals lacking skeletal maturity; pregnant or nursing women; patients with cardiac pacemakers; on fractures due to bone cancer; or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling, at www.exogen.com or by contacting customer service at 1-800-396-4325.
†A non-union is considered to be established when the fracture site shows no visibly progressive signs of healing.
SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women or children. Risks can include general knee pain, warmth and redness at the injection site. Full prescribing information can be found in product labeling, at www.SUPARTXFX.com or by contacting customer service at 1-800-396-4325.
DUROLANE indications vary by market, but include the following: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, toes and temporomandibular and facet joints. DUROLANE is also indicated for pain following joint arthroscopy either in the presence of osteoarthritis or subsequent to general surgical repair within 3 months of the procedure.
There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Full prescribing information can be found in product labeling, at www.durolane.com or by contacting customer service at 1-800-396-4325.